AML is a remarkably heterogeneous disease. Novel treatment strategies improved outcomes in selected genetic subsets of AML. Higher dose Ara-C based regimens showed to be superior over “7 + 3” regimens. Most centers still use “7 + 3” regimen and greater awareness will improve the outcome.